Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Anti-Emetics Drugs > Flashcards

Anti-Emetics Drugs Flashcards

1
Q

Examples of Serotonin Receptor Antagonist

A

Ondansetron
Palonsetron
Dolasetron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What kind of receptors are serotonin Receptor Antagonist

A

5HT3 receptors

Na/K gated channels found in CNS/PNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What do serontonin receptor antagonist inhibit

A

central and peripheral stimulation of 5-HT3 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where are serontonin 5HT3 receptors located

A

CTZ

afferent fibers of vagus nerve in GI tract/CNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

+ of Serontonin Receptor Antagonist

A

effective do not cause sedation and well tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

when are Serotonin receptor antagonist administered

A

end of surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Side effects of serotonin receptor antagonist

A

headache, prolonged QT interval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PO Dose of Ondansetron

A

4 or 8mg

for PONV prophylaxis 16mg PO x1 hour prior to induction of anesthesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

IV Dose of Ondansetron

A

4mg single dose

0.1mg/kg if less the 40kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Half life of Ondansetron

A

4 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Onset of Ondansetron

A

30 mins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Peak Plasma of Ondansetron

A

immediately

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bioavailability of Ondanestron

A

60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How protein bound is Ondanestron

A

70-76%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Where is ondanestron metabolized?

A

liver by CYP3A4, CYP1A2, CYPD6
extensive metabolism in liver by hydroxylation and conjugation CYP450
less then 5% metabolized in kidneys (no renal dose adjustment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Elimination 1/2 life of Ondansetron

A

3-7 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Excretion of Ondansetron

A

urine

feces

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What will decrease clearance of Ondanestron

A

severe hepatic impairment due to increase in plasma 1/2 life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Side effects of Ondansetron

A

headache, dizziness, diarrhea, constipation, prolonged QTc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Palonosetron is

A

second generation serotonin antagonist

most selective- greater affinity for serontonin receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Palonosetron is one of the most effective treatments for

A

chemotherapy induced N/V and PONV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Half life of Palonosetron

A

40 hours (therapeutic effects for 72 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Palonosetron dosing for PONV

A

0.75mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Palonosetron dosing for chemo-induced N/V

A

0.25mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Excretion of Palonosetron

A

more then 80% excreted in urine over 6 days and 1/2 amount unchanged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Special considerations for palonosetron

A

no doseage adjustments for elderly, renal or hepatic patients
no safety/efficacy data in patients <18 years of age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

MOA of Dolasetron

A

reduce activity of vagus nerve to limit activation of the vomitting center in medulla oblongata

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Dose of Dolasetron

A

12.6mg IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

DOA of Dolasetron

A

4-9 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Protein binding of Dolasetron

A

69-77%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Elimination 1/2 time of Dolasetron

A

8.1 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Where is dolasetron eliminated

A

liver (CYP450) kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Onset of dolasetron

A

immediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Peak Plasma of dolasetron

A

36 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

When is the best time to give dolasetron

A

15 minutes before the end of a case

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Single dose of dolasteron

A

single oral dose 100mg 102 hours preop is effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Adverse effects of dolasteron

A

headache, dizziness, constipation, potential for QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

How is dolasteron excreted

A

urine/feces

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Dosing of Granisetron (kytril)

A

0.35-3 mg IV at end of surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Granisetron is common for

A

patients receiving chemotherapy and radiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Half life of granisetron

A

3-14 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Bioavailbility of Graniestron

A

60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Protein binding of graniestron

A

64%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Excretion of graniestron

A

renal and fecal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Adverse effects of granisetron

A

headache, dizziness, and constipation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Dopamine receptor antagonist

A

D2 receptors in GI tract sends signals to CNS to induce nausea and vomiting in vomiting center

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Dopamine receptor antagonist are contraindicated in

A

parkinson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Side effects of dopamine receptor antagonist

A

extrapyramidal side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Dopamine Receptor antagonists are also known as

A

butyrophenone class

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

MOA of Droperidol

A

blocks dopamine receptors that contribute to development of PONV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Properties of Droperidol

A

anxiolytic, sedative, hypnotic and antiemetic properties

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Dose of Droperidol

A

0.625-1.25mg IV (SLOW) or IM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Onset of Droperidol

A

3-10 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Peak of Droperidol

A

30 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

DOA of droperidol

A

2-4 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Where is droperidol metabolized

A

lver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Excretion of droperidol

A

urine (unchanged) and feces

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Unwanted side effect of Droperidol

A

qt prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Dose of Droperidol effective at reducing vomiting

A

10-20mcg/kg

60
Q

What dose of droperidol is superioir to metoclopramide PO in reducing PONV

A

20mcg/kg immediately after induction

61
Q

20 mcg/kg of droperidol causes

A

prolonged sedation

62
Q

High dose of droperidol (50-75mg/kg) causes

A

increased side effects: anxiety, dizziness, drowsiness, hypotension, extrapyramidal side effects

63
Q

Droperidol requires

A

12 Lead EKG of patients 2-3 hours after administration

64
Q

Prochlorperazine class

A

Phenothiazine

Anti-psychotic/antiemetic

65
Q

MOA of prochlorperazine

A

affects multiple receptros

histaminergic, dopaminergic (D2 blockade), muscarinic

66
Q

Prochlorperazine is used for

A

PONV prophylaxis

67
Q

Dose of Prochlorperazine

A

5-10mg IM/IV before induction

68
Q

DOA of Prochlorperazine

A

3-4 hours

69
Q

Protein Binding of Prochlorperazine

A

91-99%

70
Q

Peak onset Prochlorperazine

A

2-4 hours

71
Q

Prochlorperazine is primarily metabolized by

A

liver (CYP2D6/CYP3A4)

72
Q

Prochlorperazine elimination half life

A

6-10 hours (IV)

73
Q

Excretion of Prochlorperazine

A

biliary inactive metabolites in urine

74
Q

Side effects of Prochlorperazine

A

extrapyramidal and anticholinergic side effects

sedation, blurred vision, hypotension, dizziness, neuroleptic malignant, syndrome, restlessness and dystonia

75
Q

Benzamide

A

Metoclopramide

76
Q

MOA of Metoclopramide

A

centrally acting dopamine receptor antagonist in CTZ/vomiting center (peripherally acting as cholinomimetic in GI tract (facilitates Ach transmission at muscarinic receptors)

77
Q

Metoclopramide will

A

increase LES tone, speeds gastric emptying time, lowers gastric fluid volume

78
Q

Metoclopramide is effective for

A

gastroparesis, GERD, aspiration pneumonia prophylaxiss

79
Q

Dose of Metoclopramide

A

10 mg IV (range 5-20mg) or 0.1-0.25mg/kg IV q6h

80
Q

Metoclopramide must be administered

A

slowly over 1-2 minutes, if not abdominal cramping

81
Q

studies show that Metoclopramide is

A

ineffective at lower doses, unless used in combination with other anti-emetics

82
Q

Advantage of Metoclopramide

A

lack of sedative properties

83
Q

Onset of Metoclopramide

A

3-4 minutes IV

84
Q

Peak of Metoclopramide

A

1-2 hours

85
Q

DOA of Metoclopramide

A

1-2 hours

86
Q

Metabolism of Metoclopramide

A

liver

87
Q

Elimination of Metoclopramide

A

renal excretion

elimination 1/2 life: 5-6 hours

88
Q

adverse effects of Metoclopramide

A

extrapyramidal side effects

89
Q

Metoclopramide C/A in

A

parkinson’s disease, seziure, GI obstruction and pheochromocytoma

90
Q

Haloperidol belongs to what drug class

A

butyrophenone

91
Q

Dose of Haloperidol

A

0.5-2mg

92
Q

Is haloperidol approved by FDA for anti-emetic

A

no

93
Q

When do you administer Haloperidol

A

beginning or end of surgery

94
Q

Amisulpride is

A

a D2 adn D3 receptor antagonist

95
Q

Dose of Amisulpride

A

5-10mg IV

96
Q

Side effects of Amisulpride

A

mild increase in prolactin level

97
Q

What drug is not associated with sedation, EP or QTc prolongation

A

amisulpride

98
Q

Dose of perphenazine

A

5mg IV

99
Q

What is perphenazine

A

atypical antipyschotic and dopamine receptor antagonist

100
Q

Neurokinin 1 receptor antagonist

A

found in nucleus of solitary tract and regulate visceral function
provide antemetic activity by suppressing activity at NTS

101
Q

Aprepitant (Emend)

A

neurokinin 1 receptor antagonist

102
Q

MOA of aprepitant

A

inhibit substance P at central and peripheral receptors

103
Q

Does aprepitant have sedative effects?

A

no

104
Q

Long half life of aprepitant

A

9-13hours

105
Q

Dose of aprepitant

A

40-80mg PO preop

106
Q

Aprepitant is recommended for

A

high risk nonpregnant patients

107
Q

Metabolism of aprepitant

A

liver

108
Q

Bioavailability of Aprepitant

A

60-65%

109
Q

Protein binding of aprepitant

A

> 95%

110
Q

Excretion of aprepitant

A

feces and urine

111
Q

adverse effects of aprepitant

A

fatigue, dizziness, hypoesthesia, disorientation, N/D, anorexia, constipation, diarrhea, dyspepsia, heartburn, ab pain, gastritis, perforating duodenal ulcer, hiccups

112
Q

When administer dexamethasone + aprepitant

A

reduce dose by 1/2 to maintain dexamethasone plasma concentrations

113
Q

Histamine-receptor Antagonist

A

dramamine dimenhydrinate

Promethazine

114
Q

MOA of Dimenhydrinate

A

H1 antagonist competes with histamine at H1 receptor sites in GI tract, blood vessels and respiratory tract; blocks CTZ, depresses labyrinthine function and vestibular stimulation

115
Q

Adverse effects of dimenhydrinate

A

drowsiness, urinary retention, dry mouth, blurred vision, extrapyramidal effects, commonly causes sedation

116
Q

Dose of dimenhydrinate

A

50-100mg IV/IM q4h

117
Q

Max dose of Dramamine

A

100mg 4hours

118
Q

onset of dramamine

A

immediate

119
Q

duration of dramamine

A

4-6 hours

120
Q

metabolism of dramamine

A

liver

121
Q

excretion of dramamine

A

metabolites excreted in urine

122
Q

MOA of phenergan

A

Antihistamine (H1) antagonist and anticholinergic/ muscarinic blocking effects responsible for antiemetic properties

123
Q

Dose of Promethazine

A

12.25mg q4-6h

124
Q

DOA of promethazine

A

4-6 hours

125
Q

Metabolism of Promethazine

A

hepatic (glucuronidation and sulfoxidation)

126
Q

Elimination of Promethazine

A

kidney/biliary

127
Q

Elimination 1/2 life of promethazine

A

10-19 hours

128
Q

bioavailibility and protein binding of promethazine

A

88% and 93%

129
Q

Common side effects of Promethazine

A

confusion, drowsiness, dry mouth, constipation (no for patient >65yrs)
significant sedation

130
Q

MOA of scopolamine

A

muscarinic antagonist
inhibits action of ach at parasympathetic sites in smooth muscle, CNS and secretory glands
block communication between nerves of vestibule and vomit center in brainC

131
Q

Scopolamine structure and solubility

A

tertiary amine

lipid soluble

132
Q

Side effects of scopolamine

A

cerebral depression, sedation and amnesia

CNS side efffcts

133
Q

Anticholinergic posioning

A

agitation delirium dry mouth tachycardia, impaired vision hallucinations unconciousness

134
Q

Treatment for anticholinergic OD

A

physostigimine 0.01-0.03mg/kg IV repeat 15-30 mins

135
Q

Scopolamine C/a in pateint

A

closed angle glaucoma

136
Q

Dose of Scopolamine

A

1.5 mg topical patch behind ear

137
Q

Onset of scopolamine

A

2-4 hours

138
Q

DOA of scopolamine

A

72 hours

139
Q

Metabolism of scopolamine

A

liver

140
Q

elimination of scopolamine

A

4.5 hours

141
Q

excretion of scopolamine

A

kidneys

142
Q

Scopolamine should be avoided in

A

patients over 65 years of age

143
Q

Adverse effects of scopolamine

A

dry mouth, increased thirst, dry skin, constipation, drowsiness, dizziness, blurred vision, dilated pupils, light sensitivity

144
Q

Ephedrine Class

A

indirect-acting sympathomimetic agent

145
Q

Dose of Ephedrine

A

10-25mg IV recommended for n/v associated with postual hypotension in PACU

146
Q

MOA of Benzo

A

decreases dopamine’s emetic effect in the CTZ and decreases release of serontonin by binding to GABA receptor complex

Pharmacology (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions